Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (799)	5/2/2003 9:41:25 PM
From: Miljenko Zuanic	Respond to of 3559

It started! Press Release Source: Milberg Weiss Bershad Hynes & Lerach LLP Milberg Weiss Announces The Filing Of A Class Action Suit Against Regeneron Pharmaceuticals, Inc., Leonard S. Schleifer, George D. Yancopoulos, Hans-Peter Guler, Neil Stahl and Murray A. Goldberg Friday May 2, 8:25 pm ET NEW YORK--(BUSINESS WIRE)--May 2, 2003--The law firm of Milberg Weiss Bershad Hynes & Lerach LLP announced that a class action lawsuit was filed on May 2, 2003, on behalf of purchasers of the securities of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (Nasdaq:REGN - News) between March 28, 2000 and March 30, 2003, inclusive, (the "Class Period"), and who suffered damages thereby.

To: Miljenko Zuanic who wrote (799)	5/4/2003 7:12:52 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3559

Among several VEGF-Trap abstract at AVOR, one work is with Noivartis collaboration. REGN need infusion from outside, that is for sure. Even IL-1 Trap is tested in corneal inflammation. Program#/Poster#: 3920/B623 Abstract Title: VEGF-TRAPR1R2 Suppresses Choroidal Neovascularization(CNV) and VEGF-Induced Breakdown of the Blood-Retinal Barrier(BRB) Presentation Start: Wednesday, May 07, 2003, 10:30 AM -12:30 PM Reviewing Code: 110 angiogenesis: basic mechanisms - RC Author Block: Y.Saishin1, Y.Saishin1, K.Takahashi1, R.Lima Silva1, D.Hylton2, J.S. Rudge2, S.J. Wiegand2, P.A. Campochiaro1. 1Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD; 2Regeneron Pharmaceuticals, Tarrytown, NY. Keywords: 390 drug toxicity/drug effects,567 retinal neovascularization,484 neovascularization Purpose: VEGF-TRAPR1R2 is a fusion protein that combines ligand binding elements taken from the extracellular domains of VEGF receptors 1 and 2 fused to the Fc portion of IgG1. It is a specific inhibitor of VEGF. The purpose of this study was to investigate the effect of VEGF-TRAPR1R2 in models of CNV, subretinal NV, and breakdown of the BRB. Methods: : The effect of subcutaneous injections of VEGF-TRAPR1R2 was tested in mice with laser-induced rupture of Bruch's membrane, transgenic mice that express VEGF in photoreceptors, and in two models of VEGF-induced breakdown of the BRB. Results: Subcutaneous injections or a single intravitreous injection of VEGF-TRAPR1R2 strongly suppressed CNV in mice with laser-induced rupture of Bruch's membrane. Subcutaneous injections of VEGF-TRAPR1R2 also significantly inhibited subretinal NV in rhodopsin/VEGF transgenic mice, and significantly reduced BRB breakdown in mice in which recombinant VEGF was injected into the vitreous cavity and in double transgenic mice with doxycycline-induced expression of VEGF in the retina. Conclusions: These data confirm that VEGF is a critical stimulus for the development of CNV and indicate that VEGF-TRAPR1R2 may provide a new agent for treatment of patients with CNV and diabetic macular edema. Commercial Relationship: Y. Saishin, None; Y. Saishin, None; K. Takahashi, None; R. Lima Silva, None; D. Hylton, Regeneron Pharmaceuticals E; J.S. Rudge, Regeneron Pharmaceuticals E; S.J. Wiegand, Regeneron Pharmaceuticals E; P.A. Campochiaro, Novartis Ophthalmics F, C, R; Alcon F; RW Johnson F.